PCOS Has a New Name — PMOS – and a Better Future

In this article

For years, polycystic ovary syndrome (PCOS) was one of medicine’s most frustratingly misleading names. The condition was often described as a problem of “cysts on the ovaries,” even though many patients never had those cysts and the real disorder involved a much wider hormonal and metabolic imbalance. 

That confusion is now being corrected. In May 2026, an international consortium announced that PCOS will be renamed polyendocrine metabolic ovarian syndrome, or PMOS, after a 14-year effort to find a name that better reflects the condition and does less harm to patients. 

The old term created a narrow, and often wrong, mental picture. It made the syndrome sound like a localized ovarian disorder, when, in reality, PCOS affects endocrine signaling, metabolism, reproductive function, skin, weight regulation, and mental health. 

That mismatch mattered in everyday care. Patients were sometimes dismissed because they did not have “cysts,” even though ovarian cysts are not required for diagnosis. The name also encouraged both patients and providers to underestimate the condition’s broader health effects. 

The new name was designed to fix that. Experts said the agreed principles behind PMOS included patient benefit, scientific accuracy, ease of communication, cultural appropriateness, stigma reduction, and implementation planning. 

This change did not happen overnight. The renaming process took 14 years of global collaboration, with a major push beginning around 2015, when experts met in Sicily and began debating a better name. 

The process eventually drew on input from more than 50 patient and professional organizations and around 22,000 people across six continents. That kind of scale is unusual, but it reflects how common PCOS is and how deeply the name affected diagnosis, treatment, and public understanding. 

A three-year transition is now planned, with both names used during the changeover and PMOS expected to be fully incorporated into the 2028 international guideline update. 

PMOS stands for polyendocrine metabolic ovarian syndrome. The wording is deliberate: “polyendocrine” signals that multiple hormone systems are involved, “metabolic” highlights the insulin and weight-related aspects, and “ovarian” keeps the reproductive connection visible without making it the whole story. 

That broader framing helps explain why people with the condition can experience very different symptom patterns. Some mainly struggle with irregular cycles or fertility problems, while others notice acne, hair growth, hair thinning, fatigue, or signs of insulin resistance. 

The diagnosis process for PMOS has not changed. The WHO and NHS both describe the core criteria as meeting at least two of three features after other causes are excluded: 

• irregular or absent ovulation
• signs or symptoms of androgen (male hormone) excess, and 
• polycystic ovaries on ultrasound. 

That means a person can have the condition without visible ovarian cysts. It also means the evaluation should be broad, because thyroid disease, adrenal problems, and other endocrine disorders can mimic or overlap with the same symptoms. 

‍

The symptoms of PMOS are varied and include:

• Irregular, infrequent, or missed periods.
• Trouble ovulating and getting pregnant, infertility.
• Acne or oily skin.
• Excess facial or body hair.
• Thinning hair on the scalp.
• Weight gain or difficulty losing weight.
• Darkened skin patches, especially on the neck or under the arms.
• Skin tags.
• Fatigue.
• Mood changes.
• Sleep problems.
• Signs of insulin resistance, which may include increased appetite or blood sugar issues.

The symptom complexity is part of why a more accurate name matters: it reminds everyone that this is not a single-issue diagnosis. 

PCOS care has become more personalized in recent years, and the 2023 international guideline reflects that shift. The guideline contains 254 recommendations and practice points, emphasizing symptom-based, goal-based treatment rather than a rigid one-path-fits-all approach. 

For many patients, care starts with lifestyle support aimed at improving metabolic health and insulin sensitivity. Medications often include combined oral contraceptives for cycle regulation and androgen-related symptoms, metformin for metabolic dysfunction, and fertility medications when pregnancy is the goal. 

The most notable trend is the growing focus on metabolism. Recent reviews discuss GLP-1 receptor agonists as a promising option for some patients with PCOS who also have obesity or insulin resistance, though the use of GLP-1s is still evolving and not yet standard for everyone. 

There is also continuing interest in inositol supplements, but the evidence is mixed and not as strong as some marketing suggests. Metformin remains the best-established metabolic medication in the PCOS toolkit, even if it is not ideal for every patient. 

PMOS and Hashimoto’s hypothyroidism overlap more often than many people realize, which is one reason the new name matters. Research has found a significant association between PCOS and Hashimoto’s thyroiditis, as well as between PCOS and subclinical hypothyroidism, suggesting that the same patient may be dealing with more than one endocrine issue at once.

That overlap can make symptoms easier to miss or misattribute. Fatigue, weight gain, irregular periods, brain fog, constipation, hair thinning, and fertility problems can be caused by hypothyroidism, PMOS, or both, so patients are sometimes told that all of their symptoms belong to a single diagnosis when that is not actually true.

Clinically, that means thyroid testing should be part of a thoughtful evaluation when PMOS is suspected or already diagnosed. Several reviews recommend screening for thyroid dysfunction in people with PCOS-like symptoms, and also considering PMOS in patients with known thyroid disease who have androgen-related symptoms, cycle irregularity, or infertility.

For patients, the connection is important because treating hypothyroidism can make a meaningful difference in how well PMOS symptoms are controlled. If thyroid disease is present and left untreated, it can worsen metabolic and reproductive problems, so identifying both conditions can lead to a clearer plan, better symptom relief, and a more complete explanation of what is going on.

The rename is a win because it tells the truth more clearly. It acknowledges that this is a systemic endocrine-metabolic disorder, not just an ovarian problem, which should improve communication between patients and clinicians. 

It may also reduce stigma. People with PCOS have often described feeling blamed, minimized, or confused by a label that did not match their experience, and a more accurate name can help normalize the seriousness of the condition. 

There is a diagnostic benefit too. If clinicians think in terms of PMOS, they are more likely to look for metabolic risk, mental health effects, fertility issues, and thyroid disease – rather than stopping at a single ultrasound result. 

The timing of the renaming is important because awareness around women’s endocrine health has grown, but care gaps remain large. The 2023 guideline and the 2026 name change both point to the same reality: PCOS has been under-recognized, under-explained, and sometimes under-treated for too long. 

A new name will not solve everything, but it can reshape the conversation. Medical language influences research priorities, clinical habits, insurance coding, patient education, and public understanding, so changing the label is more than cosmetic. 

For now, patients will likely see both PCOS and PMOS during the transition, which is normal when a long-established medical term is updated. But the direction is clear: the field is moving toward a more precise, more respectful, and more useful name. 

That is good news for patients who have spent years trying to make sense of symptoms that were never just about the ovaries. PMOS says the quiet part out loud: this condition is hormonal, metabolic, reproductive, and real. 

When hormonal symptoms overlap, getting the right diagnosis and comprehensive care matters. Paloma Health offers a patient-centered approach to thyroid and hormonal healthcare, with specialized support for conditions like hypothyroidism, Hashimoto’s, and related endocrine issues that can intersect with PMOS. By looking at the full picture—including metabolism, thyroid health, symptoms, and lab testing—Paloma helps patients better understand their health and access personalized treatment designed for long-term wellness.

What is PMOS?

PMOS stands for polyendocrine metabolic ovarian syndrome, the new name for PCOS. The updated name better reflects the hormonal, metabolic, and reproductive aspects of the condition instead of focusing only on the ovaries.

Why was PCOS renamed?

Experts felt the old name was misleading because many patients with PCOS do not actually have ovarian cysts. The new name is intended to improve understanding, reduce stigma, and encourage more accurate diagnosis and treatment.

Are PMOS and PCOS the same condition?

Yes. PMOS is the new name for the condition previously known as PCOS, but the diagnosis and core medical understanding remain the same.

What are the most common symptoms of PMOS?

Symptoms may include irregular periods, infertility, acne, excess facial or body hair, hair thinning, fatigue, weight gain, insulin resistance, and mood changes. Not everyone experiences the same symptoms, which is why the condition can sometimes be difficult to recognize.

Can you have PMOS without ovarian cysts?

Yes. Many people diagnosed with PMOS do not have ovarian cysts on ultrasound, which was one of the major reasons experts pushed for a name change.

How is PMOS diagnosed?

Doctors generally diagnose PMOS based on a combination of irregular ovulation, signs of elevated androgen hormones, and ultrasound findings after ruling out other conditions. A person typically needs two out of these three features for diagnosis.

Is PMOS linked to thyroid disease?

Research suggests there is a strong overlap between PMOS and thyroid conditions such as Hashimoto’s thyroiditis and hypothyroidism. Because symptoms can overlap, thyroid testing is often an important part of a complete evaluation.

Does PMOS affect weight and metabolism?

Yes. Many people with PMOS experience insulin resistance, weight gain, difficulty losing weight, or blood sugar issues. That metabolic component is one reason the condition’s new name now includes the word “metabolic.”

What treatments are available for PMOS?

Treatment depends on symptoms and health goals. Options may include nutrition and lifestyle support, birth control pills, metformin, fertility medications, and in some cases newer GLP-1 medications for metabolic health.

Will everyone start using the name PMOS immediately?

No. Experts expect a gradual transition over the next several years, and both PCOS and PMOS will likely be used together for a while. International guidelines are expected to fully adopt PMOS by 2028.